Questions: High-Affinity IgE Receptor and Mast Cell Activation

Question 1

A patient is first exposed to a pollen allergen. Their immune system produces IgE antibodies specific to this allergen, which then bind to FcεRI on mast cells in nasal mucosa. The next time the patient encounters the pollen, what triggers mast cell degranulation?

• A. IgE binding to FcεRI — the same event that armed the mast cell originally
• B. Cross-linking of multiple IgE-FcεRI complexes by the multivalent allergen binding to two or more IgE molecules simultaneously
• C. The allergen binding directly to FcεRI without IgE involvement, since the receptor is already sensitized
• D. ACTH release from the pituitary, which signals mast cells to degranulate upon re-exposure

Answer: (B)

IgE binding to FcεRI alone does nothing — the mast cell can remain armed with IgE for weeks to months without releasing a single granule. The critical trigger for degranulation is cross-linking: the allergen (typically a multivalent protein with multiple binding sites) must physically bridge two or more IgE molecules on the cell surface, pulling their FcεRI receptors together. This receptor aggregation clusters the ITAM motifs on the receptor's cytoplasmic tails, initiating the kinase cascade (Lyn → Syk → PLC) that ultimately drives calcium release and granule fusion. Without cross-linking, no signal is initiated regardless of how many IgE molecules are bound.

Question 2

A patient takes an antihistamine before allergen exposure. Their mast cells still degranulate normally in response to allergen cross-linking, but their symptoms are reduced. What does this tell us about where antihistamines act?

• A. Antihistamines block IgE from binding to FcεRI, preventing mast cell arming
• B. Antihistamines stabilize mast cell membranes to prevent granule fusion during degranulation
• C. Antihistamines act downstream of degranulation, blocking histamine receptors on target tissues rather than preventing histamine release
• D. Antihistamines inhibit the Syk kinase step in the FcεRI signaling cascade

Answer: (C)

Antihistamines are receptor antagonists that compete with histamine at H1 receptors on target tissues (blood vessels, smooth muscle, nerve endings) — they do not prevent mast cells from degranulating or releasing histamine. The degranulation cascade proceeds normally, releasing histamine into tissues, but the histamine cannot bind its receptor and trigger symptoms. This is why antihistamines are incomplete therapies for severe allergic reactions: they block only the histamine component of the response, leaving prostaglandins, leukotrienes, and cytokines to produce ongoing symptoms. Mast cell stabilizers (like cromolyn) act earlier, preventing degranulation itself.

Question 3

IgE binding to FcεRI on a mast cell immediately triggers histamine release.

• T. True
• F. False

Answer: False

False — and this is the central misconception about FcεRI signaling. IgE binding to FcεRI is necessary but not sufficient for mast cell activation. A mast cell can carry thousands of IgE molecules bound to FcεRI for weeks to months without releasing a single granule. Activation requires cross-linking of FcεRI molecules by a multivalent allergen — the physical clustering of receptors is the actual trigger that initiates the signaling cascade. This is why sensitized individuals (who have IgE-armed mast cells) can circulate freely until allergen exposure, at which point the cross-linking event triggers the immediate response.

Question 4

Mast cells in tissues can remain sensitized (armed with allergen-specific IgE) for weeks to months without spontaneously activating.

• T. True
• F. False

Answer: True

True. FcεRI has extraordinarily high affinity for IgE — roughly 10⁸ to 10⁹ M⁻¹ — making the IgE-FcεRI interaction essentially irreversible under physiological conditions. IgE molecules can remain bound to mast cell surfaces for weeks to months, maintaining the cells in a sensitized state. This prolonged sensitization is what allows a severe allergic reaction to occur months after initial sensitization, and why patients with known severe allergies remain at risk long after allergen avoidance. The therapeutic logic of anti-IgE biologics (omalizumab) follows from this: intercepting free IgE before it arms mast cells can deplete the sensitized state over time.

Question 5

Why does mast cell activation require cross-linking of FcεRI rather than simply IgE binding to the receptor? Explain in terms of the signaling mechanism.

Model answer: Cross-linking is required because the FcεRI signaling cascade is initiated by receptor aggregation, not by receptor occupancy alone. When a multivalent allergen bridges two or more IgE-FcεRI complexes, it physically brings multiple receptor cytoplasmic tails into close proximity. This clustering allows the constitutively associated Src-family kinase Lyn to transphosphorylate the ITAM sequences on the β and γ chains of neighboring receptors — a reaction that requires the ITAMs to be in close proximity. A single occupied FcεRI receptor has its cytoplasmic tail too isolated for this transphosphorylation to occur efficiently. Once ITAMs are phosphorylated, Syk is recruited and activated, leading to PLC activation, IP3-driven calcium release, and ultimately granule fusion with the plasma membrane.

This cross-linking requirement is a general principle in immune receptor signaling — TCR, BCR, and many cytokine receptors also require receptor clustering for activation. It serves as a threshold mechanism: a single allergen molecule (or a monovalent hapten) cannot activate mast cells, requiring multivalent allergen engagement that is more characteristic of genuine pathogen exposure. The cross-linking requirement explains why a monomeric IgE molecule floating in circulation doesn't trigger inflammation at every mast cell it encounters, and why therapeutic monoclonal antibodies targeting IgE (omalizumab) can bind IgE without triggering the cells they're trying to protect.